Raydiant Oximetry Raises $7.5M in Funding to Improve Childbirth Outcomes
Raydiant Oximetry Raises $7.5M in Extension Series A
Raydiant Oximetry's Series A3 Extension Funding
Key Highlights:
- Series A3 Extension Funding: Raydiant Oximetry, a clinical-stage medical device company, raised $7.5 million in funding.
- Investors: Cross-Border Impact Ventures led the round, with participation from RH Capital, Global Health Impact Fund, VCapital, and the March of Dimes Innovation Fund.
- Technology Focus: Raydiant Oximetry has developed two innovative technologies, Lumerahâ„¢ and DaisyTM, aimed at improving outcomes for mothers and babies during childbirth.
Raydiant Oximetry's Target Market
- Target Market: Healthcare providers and hospitals specializing in obstetrics and gynecology, particularly those focused on improving outcomes during childbirth.
- Medical Device Manufacturers: Companies seeking innovative technologies for fetal oxygenation monitoring and post-partum hemorrhage prevention.
- Research Institutions: Organizations involved in clinical studies and research related to maternal and fetal health.
What Raydiant Oximetry Needs to Buy
- Clinical Research Support: Collaborations with research institutions and hospitals for conducting clinical studies on the LumerahTM and DaisyTM technologies.
- Manufacturing and Supply Chain Solutions: Partnerships with manufacturers to produce and distribute their medical devices.
- Marketing and Sales Expertise: Engaging with marketing agencies and sales experts to effectively reach their target market and healthcare providers.